- The trend backdrop is active with a 5-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
UNICHEMLAB
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Unichem Laboratories Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
489.8 INR
-4.9%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 22.1% above the Trend Line and sits at 51.7% of its 52-week range. The latest completed week returned -4.9%, after a -23.3% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
37
out of 100
Latest Close
489.8 INR
7 Aug 2026
1W Return
-4.9%
latest completed week
4W Return
-23.3%
short-term follow-through
12W Return
31.5%
quarterly tape
Trend Breadth
9.6%
5 of 52 weeks active
Volume Ratio
0.2x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- The share remains more than 20% below its 52-week high.
- Recent volatility is running well above the one-year baseline.
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-4.9%
Latest completed week; four-week move -23.3%.
Indicator stack
23/67
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
50/100
16 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 22.1% above the Trend Line and sits at 51.7% of its 52-week range. The latest completed week returned -4.9%, after a -23.3% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.2x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.6212-week average 0.34
12-week confirmation
Trend active5/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership9/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.62Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -23.3% over four weeks, 31.5% over 12 weeks, and -1.6% over one year. The current trend has remained active for 5 consecutive weeks.
Performance by holding period
Active trend streak5 weeks
Active weeks in one year5
Trend breadth9.6%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.07Latest activity-pressure read.
Pressure change-27.3%Four-week change in activity pressure.
Leadership14.52Latest relative-leadership reading.
RS change-71.1%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 94%
Model confidence 88%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength28/100Blend of value, momentum, and quality. Underlying universe rank 73; rank 1 is best.
Value41/100Relative valuation strength. Underlying universe rank 60; rank 1 is best.
Quality17/100Profitability and accounting quality. Underlying universe rank 84; rank 1 is best.
Momentum69/100Medium-term price momentum. Underlying universe rank 32; rank 1 is best.
Growth69/100Revenue and earnings growth. Underlying universe rank 32; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework3/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 13.6x Price divided by trailing earnings.
- Price / sales
- 1.6x Market value relative to trailing revenue.
- EV / EBITDA
- 8.1x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -3.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 53.7% Gross profit retained from each unit of revenue.
- Operating margin
- 2.5% Operating profit retained from revenue.
- Free-cash-flow margin
- -5.4% Free cash flow generated from revenue.
- Return on invested capital
- 1.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 4.6% Latest one-year revenue growth.
- EPS growth
- 83.9% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.5x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 16 relevant articles.
1 positive · 14 neutral · 1 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-28.7%Distance below the 52-week high.
13-week volatility12.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2616 weeks finished lower.
Best week+35.0%Week of 10 Jul.
Worst week-9.4%Week of 27 Mar.
Latest week-4.9%Week of 7 Aug.
Shape of recent returns
Strong gains8
Modest gains2
Flat weeks0
Modest losses7
Sharp losses9
Recent vol12.5%13-week weekly-return volatility.
Base vol7.3%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew5.5% / -3.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank99 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank92 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape41/100
Trend, activity pressure, participation, and risk combine to a 41/100 tape read.
Indicator analysis65/100Latest 12-week confirmation: trend 5/12, activity pressure 12/12, relative leadership 9/12.
Activity pressure 0.62; No reversal markers Factors36/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 62; Small Cap Core rank 38 SVQF3/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1526.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 16 relevant articles.
Unichem Laboratories closes trading window from July 1 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 489.8 INR | -4.9% | 401.0 INR | 529.2 INR | 1.07 | 14.52 | 282.9K | On |
| 31 Jul 2026 | 514.9 INR | -4.2% | 398.6 INR | 528.7 INR | 1.40 | 21.25 | 260.7K | On |
| 24 Jul 2026 | 537.3 INR | -8.8% | 396.2 INR | 527.9 INR | 1.56 | 29.30 | 739.4K | On |
| 17 Jul 2026 | 589.0 INR | -7.8% | 393.1 INR | 526.9 INR | 1.55 | 38.00 | 1.4M | On |
| 10 Jul 2026 | 638.8 INR | 35.0% | 388.4 INR | 525.6 INR | 1.47 | 50.28 | 14.7M | On |
| 3 Jul 2026 | 473.0 INR | 9.2% | 382.3 INR | 524.0 INR | 1.42 | 11.34 | 102.9K | Off |
| 26 Jun 2026 | 433.0 INR | -2.5% | 381.4 INR | 523.4 INR | 1.18 | 2.40 | 0 | Off |
| 19 Jun 2026 | 444.3 INR | -0.7% | 382.6 INR | 523.0 INR | 1.03 | 4.67 | 195.6K | Off |
| 12 Jun 2026 | 447.6 INR | 23.3% | 383.3 INR | 522.5 INR | 0.90 | 6.63 | 2.0M | Off |
| 5 Jun 2026 | 363.0 INR | 3.9% | 383.9 INR | 522.0 INR | 0.64 | -13.09 | 13.5K | Off |
| 29 May 2026 | 349.4 INR | -5.8% | 387.2 INR | 522.1 INR | 0.73 | -17.73 | 154.9K | Off |
| 22 May 2026 | 370.9 INR | -0.4% | 391.2 INR | 522.2 INR | 0.91 | -14.16 | 135.2K | Off |
| 15 May 2026 | 372.4 INR | -3.5% | 394.5 INR | 522.2 INR | 1.05 | -14.44 | 96.9K | Off |
| 8 May 2026 | 385.8 INR | -1.1% | 397.6 INR | 522.2 INR | 0.99 | -14.03 | 102.8K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.